Patents by Inventor Mark R. Bray

Mark R. Bray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALT AND CRYSTAL FORMS OF 4-AMINO-5-(6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZO[D]IMIDAZOL-2-YL)THIENO[2,3-B]PYRIDIN-6(7H)-ONE
    Publication number: 20230174549
    Abstract: A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed. (I), Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.
    Type: Application
    Filed: May 10, 2021
    Publication date: June 8, 2023
    Inventors: Mark R. Bray, Sze-Wan Li
  • COMBINATION THERAPIES FOR INHIBITION OF POLO-LIKE KINASE 4
    Publication number: 20230165871
    Abstract: Provided herein are methods of treating triple negative breast cancer using an effective amount of Compound (I) represented by the formula: or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Uses of an effective amount of Compound [I] and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-linhibitor or a PD-L1 inhibitor for treating triple negative breast cancer are also provided herein.
    Type: Application
    Filed: April 5, 2021
    Publication date: June 1, 2023
    Inventors: Graham Fletcher, Jacqueline M. Mason, Mark R. Bray
  • METHODS FOR TREATING CYTOKINE RELEASE SYNDROME
    Publication number: 20230144869
    Abstract: Disclosed herein is a method of treating a subject with aberrant cytokine release from a disease or condition or at risk of developing aberrant cytokine release from a disease or condition. The method comprises administering to the subject an effective amount of a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof. The variables in structural formula (I) are as described herein.
    Type: Application
    Filed: April 12, 2021
    Publication date: May 11, 2023
    Inventors: Mark R. Bray, Jacqueline M. Mason, Xin Wei, Gordon Duncan
  • TREATMENT FOR ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME
    Publication number: 20230010772
    Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 12, 2023
    Inventors: Mark R. Bray, Jacqueline M. Mason, Graham Fletcher
  • TSG-6 ANTIBODIES AND USES THEREFOR
    Publication number: 20220153834
    Abstract: The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Application
    Filed: March 11, 2020
    Publication date: May 19, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • LILRB3-BINDING MOLECULES AND USES THEREFOR
    Publication number: 20220089723
    Abstract: The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation This invention can also be used to modulate osteoclast differentiation.
    Type: Application
    Filed: January 16, 2020
    Publication date: March 24, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • FCMR-Binding Molecules and Uses Thereof
    Publication number: 20220089725
    Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Application
    Filed: February 14, 2020
    Publication date: March 24, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20210261554
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: December 26, 2020
    Publication date: August 26, 2021
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • COMBINATION THERAPIES FOR INHIBITION OF POLO-LIKE KINASE 4
    Publication number: 20210060026
    Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 4, 2021
    Inventors: Jacqueline M. Mason, Mark R. Bray, Tak Wah Mak, Graham Fletcher
  • RIPK2 inhibitors and method of treating cancer with same
    Patent number: 10875863
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: December 29, 2020
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20190225617
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: January 28, 2019
    Publication date: July 25, 2019
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 inhibitors and method of treating cancer with same
    Patent number: 10239881
    Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 26, 2019
    Assignee: University Health Network
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20180282335
    Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: October 9, 2015
    Publication date: October 4, 2018
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-wan Li, Jacqueline M. Mason, Mark R. Bray
  • Treatment for pancreatic cancer
    Patent number: 9642856
    Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 9, 2017
    Assignee: University Health Network
    Inventors: David W. Hedley, Ines Lohse, Jacqueline M. Mason, Mark R. Bray
  • Treatment for pancreatic cancer
    Patent number: 9555042
    Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: January 31, 2017
    Assignee: University Health Network
    Inventors: David W. Hedley, Ines Lohse, Jacqueline M. Mason, Mark R. Bray
  • TREATMENT FOR PANCREATIC CANCER
    Publication number: 20160250220
    Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2014
    Publication date: September 1, 2016
    Applicant: University Health Network
    Inventors: David W. Hedley, Ines Lohse, Jacqueline M. Mason, Mark R. Bray
  • Method of treating disease states using substituted pyrazole compounds
    Patent number: 8114870
    Abstract: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 14, 2012
    Assignee: Miikana Therapeutics, Inc.
    Inventors: Xiao-Yi Xiao, Dinish V. Patel, John S. Ward, Mark R. Bray, Gregory E. Agoston, Anthony M. Treston
  • METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS
    Publication number: 20090264422
    Abstract: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
    Type: Application
    Filed: June 30, 2009
    Publication date: October 22, 2009
    Inventors: Xiao-Yi Xiao, Dinish V. Patel, John S. Ward, Mark R. Bray, Gregory E. Agoston, Anthony M. Treston
  • Substituted pyrazole compounds
    Patent number: 7563787
    Abstract: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: July 21, 2009
    Assignee: Miikana Therapeutics, Inc.
    Inventors: Xiao-Yi Xiao, Dinish V. Patel, John S. Ward, Mark R. Bray, Gregory E. Agoston, Anthony M. Treston